Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 15/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.54 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12499541 | 1.00 | HDAC4 (0.56) | HDAC4HDAC3HDAC7HDAC8HDAC6 | |
| SCHEMBL15768963 | 0.89 | HDAC4 (0.57) | HDAC4HDAC3HDAC7HDAC8HDAC6 | |
| SCHEMBL15768961 | 0.89 | HDAC4 (0.57) | HDAC4HDAC3HDAC7HDAC8HDAC6 | |
| SCHEMBL15606831 | 0.81 | HDAC4 (0.80) | HDAC4HDAC3HDAC7HDAC8HDAC6 | |
| SCHEMBL15768918 | 0.76 | HDAC4 (0.56) | HDAC4HDAC3HDAC7HDAC8HDAC6 | |
| SCHEMBL12498080 | 0.76 | HDAC4 (0.56) | HDAC4HDAC3HDAC7HDAC8HDAC6 | |
| SCHEMBL15768564 | 0.74 | MEN1 (0.48) | HDAC4 | |
| SCHEMBL12498121 | 0.74 | MEN1 (0.48) | HDAC4 | |
| SCHEMBL15768616 | 0.74 | HDAC4 (0.46) | HDAC4 | |
| SCHEMBL12498595 | 0.74 | HDAC4 (0.46) | HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765054-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20140163009-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation (US) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163009-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | HDAC4 10/4885HDAC3 5/4885HDAC7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.